You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

LAC-HYDRIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Lac-hydrin, and what generic alternatives are available?

Lac-hydrin is a drug marketed by Sun Pharm Inds Inc and is included in two NDAs.

The generic ingredient in LAC-HYDRIN is ammonium lactate. There are forty drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the ammonium lactate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Lac-hydrin

A generic version of LAC-HYDRIN was approved as ammonium lactate by PADAGIS ISRAEL on May 1st, 2002.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LAC-HYDRIN?
  • What are the global sales for LAC-HYDRIN?
  • What is Average Wholesale Price for LAC-HYDRIN?
Summary for LAC-HYDRIN
Drug patent expirations by year for LAC-HYDRIN
Recent Clinical Trials for LAC-HYDRIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, San FranciscoPhase 4
Icahn School of Medicine at Mount SinaiPhase 4

See all LAC-HYDRIN clinical trials

US Patents and Regulatory Information for LAC-HYDRIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Inc LAC-HYDRIN ammonium lactate CREAM;TOPICAL 020508-001 Aug 29, 1996 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sun Pharm Inds Inc LAC-HYDRIN ammonium lactate LOTION;TOPICAL 019155-001 Apr 24, 1985 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for LAC-HYDRIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0496835 C960031 Netherlands ⤷  Sign Up PRODUCT NAME: DOXORUBICINESULFAAT VERKREGEN UIT DOXORUBICINEHYDROCHLORIDE EN AMMONIUMSULFAAT; REGISTRATION NO/DATE: EU/1/96/011/001 - EU/1/96/011/002 19960621
0230893 C980024 Netherlands ⤷  Sign Up PRODUCT NAME: GADOBEENZUUR,DESGEWENST IN DE VORM VAN EEN ZOUT MET EEN ALKA- LIMETAAL, AARDALKALIMETAAL, OF BASISCH GEPROTONEERD AMINOZUUR OF VAN EEN ALKYLAMMONIUM-, ALKANOLAMMONIUM- OF POLYHYDROXYAL- KYLAMMONIUMZOUT, IN HET BIJZONDER DIMEGLUMINI GADOBENAS; NAT. REGISTRATION NO/DATE: RVG 22324 19980706; FIRST REGISTRATION: GB PL 06099/0006 19970722
0266730 SPC/GB97/005 United Kingdom ⤷  Sign Up PRODUCT NAME: DOLASETRON, OR A PHARMACEUTICALLY-ACCEPTABLE ACID ADDITION OR QUATERNARY AMMONIUM SALT THEREOF; REGISTERED: UK 04425/0150 19960926
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.